CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients

Abstract Monitoring cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) is useful in predicting late-onset CMV infection after solid organ transplantation, but few data have been reported after lung transplantation (LT). CMV CMI against 2 CMV antigens (IE-1, pp65) was evaluated in 60 seropos...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2021-08, Vol.224 (3), p.526-531
Main Authors: Donadeu, Laura, Revilla-López, Eva, Jarque, Marta, Crespo, Elena, Torija, Alba, Bravo, Carles, Los Arcos, Ibai, Meneghini, Maria, Favà, Alex, Román, Antonio, Monforte, Víctor, Bestard, Oriol
Format: Article
Language:English
Subjects:
Antigens
Antiviral Agents - therapeutic use
Cell-mediated immunity
Cytomegalovirus
Cytomegalovirus Infections - drug therapy
Cytomegalovirus Infections - prevention & control
Disease prevention
Humans
Immunity, Cellular
Kidney Transplantation
Lung
Lung Transplantation
Lung transplants
Pp65 protein
Prophylaxis
Replication
Transplant Recipients
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Monitoring cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) is useful in predicting late-onset CMV infection after solid organ transplantation, but few data have been reported after lung transplantation (LT). CMV CMI against 2 CMV antigens (IE-1, pp65) was evaluated in 60 seropositive LT at 6-month prophylaxis withdrawal. LT with late-onset CMV infection showed significantly lower (IE-1)CMV CMI than patients without (P = .045), and was more evident in patients developing high viral loads (P = .010). (IE-1)CMV CMI independently predicted high first late-onset viral replication (odds ratio, 4.358; 95% confidence interval, 1.043–18.215). CMV-specific CMI may be useful in CMV preventive strategies after LT.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa727